Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/1998
06/16/1998US5767126 Alzheimer's disease treatment with tacrine metabolites
06/16/1998US5767125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
06/16/1998US5767123 Total parenteral nutrition solution containing water-soluble vitamin B
06/16/1998US5767122 Enantiomerically pure β-d-dioxolane nucleosides
06/16/1998US5767120 Antiinflammatory agents, antiallergens; treatment for septic shock
06/16/1998US5767119 Method of treating neurodegenerative diseases using an AMPA excitatory amino and an uricosuric agent
06/16/1998US5767118 4-Heterocyclic peperidines promote release of growth hormone
06/16/1998US5767117 Method for treating vascular headaches
06/16/1998US5767116 Bicyclic aromatic compounds as therapeutic agents
06/16/1998US5767115 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
06/16/1998US5767113 Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
06/16/1998US5767112 Acidic mixture for injection comprising neuromuscular blocking agent and zwitterion having isoelectric point greater than 7; shelf life, anesthetic
06/16/1998US5767111 18-nor-vitamin D compounds
06/16/1998US5767110 Combination chemotherapy
06/16/1998US5767109 Complexing urushiols
06/16/1998US5767106 Treatment of disease and conditions associated with macrophage infiltration
06/16/1998US5767104 Use of sulfated saccharides to treat baldness
06/16/1998US5767103 Nitric oxide sequestrant
06/16/1998US5767102 Antisense composition and method for treatment of CMV infection
06/16/1998US5767098 Anti-acne method and composition
06/16/1998US5767097 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
06/16/1998US5767096 Produced by culturing dactylosporangium in a bromide enriched nutrient medium
06/16/1998US5767095 Algicide
06/16/1998US5767094 Hypoglycemic agents
06/16/1998US5767092 Treatment of radiation-damaged bone marrow using galactosyl ceramides
06/16/1998US5767091 An amino acid mixture for parental injection for postoperative and/or cancer patients to potentiate narcotics or nonnarcotics and alleviate side effects; antipyretics; antispasmodic agents
06/16/1998US5766873 Administering n-acetylcysteine
06/16/1998US5766856 Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor
06/16/1998US5766640 Administering potassium bicarbonate or potassium salt of carboxylic acid which is metabolized in vivo to potassium bicarbonate
06/16/1998US5766638 Hydroxypropyl methocellulose ether compositions for reduction of serum lipid levels
06/16/1998US5766633 Modified amino acid carrier, bioactive peptides
06/16/1998US5766629 Nonionic surfactant, alkanol
06/16/1998US5766610 Useful for treatment of mammalian skin and hair, rheumatism, resipiratory system disorder, cardiovascular and vision disorders
06/16/1998US5766596 Aconite tuber-sulphur composite preparation and a process for the preparation thereof
06/16/1998US5766585 Infecting bone marrow cells with recombinant retroviral expression vector that contains a polynucleotide sequence coding a biologically active interleukin receptor antagonist protein, injecting into host; antiinflammatory agents
06/16/1998US5766581 Increasing platelet number with polypeptide molecules attached to polyethylene glycol
06/16/1998US5766580 Controlled release of miotic and mydriatic drugs in the anterior chamber
06/16/1998US5766574 Dual component tooth whitening dentifrice
06/16/1998US5766571 Method of treating human breast cancer by administration of radiolabeled antibody and unsaturated fatty acids
06/16/1998CA2224885A1 Sulfonamide-substituted compounds, processes for their preparation, their use as a medicament or diagnostic, and pharmaceutical preparations comprising them
06/16/1998CA2224670A1 Novel anthracycline derivatives having 4-amino-2,4,6-trideoxy-2-fluoro-.alpha.-l-talopyranosyl group
06/16/1998CA2165779C Novel carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
06/16/1998CA2162470C Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as the active substance
06/16/1998CA2132831C Hydrazide derivatives of 3,4-dihydro-2h-1-benzopyrans
06/16/1998CA2132457C Fluorosugar derivatives of macrolides
06/16/1998CA2119154C Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
06/16/1998CA2065965C Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a beta-adrenergic antagonist
06/16/1998CA2040374C Process for enhancing the resistance of aquatic animals to disease
06/16/1998CA2003718C Compounds
06/16/1998CA1339917C New potically-active derivatives of (r) 5-pentylamino- 5- oxopentanoic acid with antagonistic activity towards cholecystokinin and a method for their preparation
06/13/1998CA2219613A1 Crystalline form of the doxazosin mesylate and process for its production
06/11/1998WO1998025142A1 Alarm related peptides and nucleic acids and diagnosis using them
06/11/1998WO1998024923A1 Inactivation of hiv co-receptors as therapy for hiv infection
06/11/1998WO1998024922A1 Insulin-like growth factor i (igf-i) expression system and methods of use
06/11/1998WO1998024806A2 Substituted oxadiazole, thiadiazole and triazole serine protease inhibitors
06/11/1998WO1998024803A1 Steroid esters, method for the manufacture thereof and their pharmaceutical use
06/11/1998WO1998024802A2 Compound
06/11/1998WO1998024797A1 Antisense inhibition of human adhesion molecules
06/11/1998WO1998024794A1 PHENYL GLYOXAMIDES AS sPLA2 INHIBITORS
06/11/1998WO1998024793A1 Use of 7-alkylidene cephalosporins to inhibit elastase activity
06/11/1998WO1998024791A1 Benzopyranopyrrole and benzopyranopyridine alpha-1 adrenergic compounds
06/11/1998WO1998024790A1 1,4-diazabicyclo [2.2.2] oct-2-ylmethyl derivatives, their preparation and therapeutic application
06/11/1998WO1998024788A1 Tropane derivatives and method for their synthesis
06/11/1998WO1998024786A1 Trioxane dimer compounds having antiproliferative and antitumor activities
06/11/1998WO1998024785A1 Indole-urea derivatives with 5-ht antagonist properties
06/11/1998WO1998024784A1 Substituted sulfonic acid n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclamide compounds
06/11/1998WO1998024783A1 Novel n-benzenesulphonyl-l-proline derivatives, method for preparing and therapeutic use
06/11/1998WO1998024782A2 Substituted pyrimidine compounds and their use
06/11/1998WO1998024780A2 Substituted pyrimidinone and pyridinone compounds and their use
06/11/1998WO1998024778A1 Benzofuran-acrylic acid derivatives and their use as modulators of rxrs or rars receptors
06/11/1998WO1998024771A1 Benzamide derivatives having a vasopressin antagonistic activity
06/11/1998WO1998024767A1 Parasiticidal pyrazoles
06/11/1998WO1998024766A1 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
06/11/1998WO1998024765A1 Novel substituted tetrahydropyridin derivatives, method of preparation and pharmaceutical compositions containing them
06/11/1998WO1998024764A2 Substituted benzamide derivatives and pharmaceutical compositions containing them
06/11/1998WO1998024763A2 Immunotherapeutic imides/amides as pde iv and tnf inhibitors
06/11/1998WO1998024762A1 Vitamin d3 derivatives
06/11/1998WO1998024759A1 Metalloproteinase inhibitors
06/11/1998WO1998024756A1 Phenyl acetamides as spla2 inhibitors
06/11/1998WO1998024477A1 Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
06/11/1998WO1998024474A1 Inhibition of invasive remodelling
06/11/1998WO1998024470A1 Topical preparation for introducing peptidaceous pharmacons in living organisms
06/11/1998WO1998024465A1 Wound healing and treatment of fibrosis
06/11/1998WO1998024463A2 Combination therapy using a tnf binding protein for treating tnf-mediated diseases
06/11/1998WO1998024456A1 Reactive oxygen intermediates containing compounds effective in inducing cell differentiation of malignant cells such as leukemia
06/11/1998WO1998024452A1 The use of oxandrolone in the treatment of chronic fatigue syndrome
06/11/1998WO1998024451A1 Uses of oxandrolone
06/11/1998WO1998024450A1 Novel formulation
06/11/1998WO1998024449A1 The use of oxandrolone in the treatment of a neurological disorder
06/11/1998WO1998024448A1 METHOD OF PREVENTING NEURODEGENERATION AND COGNITIVE DYSFUNCTION USING 17α-DIHYDROEQUILENIN
06/11/1998WO1998024447A1 Use of nk-1 receptor antagonists for treating cognitive disorders
06/11/1998WO1998024446A1 Use of nk-1 receptor antagonists for treating movement disorders
06/11/1998WO1998024445A1 Use of nk-1 receptor antagonists for treating schizophrenic disorders
06/11/1998WO1998024444A1 Use of nk-1 receptor antagonists for treating substance use disorders
06/11/1998WO1998024443A1 Use of nk-1 receptor antagonists for treating bipolar disorders
06/11/1998WO1998024442A1 Use of nk-1 receptor antagonists for treating sexual dysfunction
06/11/1998WO1998024441A1 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
06/11/1998WO1998024440A1 Use of nk-1 receptor antagonists for treating stress disorders
06/11/1998WO1998024439A1 Use of nk-1 receptor antagonists for treating severe anxiety disorders
06/11/1998WO1998024438A1 Use of nk-1 receptor antagonists for treating major depressive disorders
1 ... 6642 6643 6644 6645 6646 6647 6648 6649 6650 6651 6652 6653 6654 6655 6656 6657 6658 6659 6660 6661 6662 ... 7860